Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2025 | $17.00 | Overweight | Wells Fargo |
| 6/10/2025 | $18.00 | Buy | Guggenheim |
| 1/30/2025 | $32.00 | Outperform | Oppenheimer |
| 10/31/2024 | $25.00 | Outperform | Robert W. Baird |
| 10/17/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/23/2024 | Overweight | Cantor Fitzgerald | |
| 7/23/2024 | $29.00 | Outperform | Leerink Partners |
| 7/23/2024 | $32.00 | Buy | Guggenheim |
8-K - ALUMIS INC. (0001847367) (Filer)
EFFECT - ALUMIS INC. (0001847367) (Filer)
10-Q - ALUMIS INC. (0001847367) (Filer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Cantor Global Healthcare Conference 2025 in New York, NY on September 3 at 9:45 am ET (fireside chat);Wells Fargo 2025 Healthcare Conference in Boston, MA on September 5 at 9:30 am ET (fireside chat);Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 8 at 4:50 pm ET (fireside chat);H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Sept
–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in Q3 2026– –Completed merger with ACELYRIN, Inc. to strengthen financial position and support advancement of late-stage immunology pipeline– –Cash, cash equivalents and marketable securities of $486.3 million as of June 30, 2025 expected to fund operations into 2027– SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical comp
-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of systemic lupus erythematosus (SLE), the most common form of lupus. "Completion of enrollment in our global LUMUS Phase 2b trial for SLE marks a significant milestone for Alumis, and importantly, for the lupus community," said Martin Babler, Presiden
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00
Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi
SC 13D - ALUMIS INC. (0001847367) (Subject)
SC 13G - ALUMIS INC. (0001847367) (Subject)
SC 13D - ALUMIS INC. (0001847367) (Subject)